Center for Scientific Review; Notice of Closed Meetings, 109-110 [2012-31451]
Download as PDF
<![CDATA[
tkelley on DSK3SPTVN1PROD with
Federal Register / Vol. 78, No. 1 / Wednesday, January 2, 2013 / Notices
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3158,
MSC 7770, Bethesda, MD 20892, 301–435–
0684, olufokunbisamd@csr.nih.gov.
Name of Committee: Oncology 1-Basic
Translational Integrated Review Group
Tumor Cell Biology Study Section.
Date: January 28–29, 2013.
Time: 8:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Charles Morrow, MD,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6202,
MSC 7804, Bethesda, MD 20892, 301–451–
4467, morrowcs@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel
Rehabilitation Sciences SEP.
Date: January 30, 2013.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Aruna K Behera, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4211,
MSC 7814, Bethesda, MD 20892, 301–435–
6809, beheraak@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: Molecular Genetics and Imaging in
Neuroscience.
Date: January 30, 2013.
Time: 2:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Paek-Gyu Lee, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4201,
MSC 7812, Bethesda, MD 20892, (301) 613–
2064, leepg@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: Endocrinology, Reproduction and
Pregnancy.
Date: January 30, 2013.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Dianne Camp, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 6164, MSC 7892, Bethesda, MD
20892, 301–435–1044,
campdm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
VerDate Mar<15>2010
16:42 Dec 31, 2012
Jkt 229001
109
Dated: December 26, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2012–31457 Filed 12–31–12; 8:45 am]
Center for Scientific Review; Notice of
Closed Meetings
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Program
Project: Conus Peptides.
Date: January 10–11, 2013.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Peter B Guthrie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4142,
MSC 7850, Bethesda, MD 20892, (301) 435–
1239, guthriep@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 21, 2012.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–31452 Filed 12–31–12; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Group Nanotechnology Study Section.
Date: January 31–February 1, 2013.
Time: 7:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Nikko San Francisco, 222
Mason Street, San Francisco, CA 94102.
Contact Person: James J Li, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5148, MSC 7849, Bethesda, MD
20892, 301–806–8065, lijames@csr.nih.gov.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group
Psychosocial Development, Risk and
Prevention Study Section.
Date: January 31–February 1, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Washington DC,
Dupont Circle, 1143 New Hampshire Avenue
NW., Washington, DC 20037.
Contact Person: Anna L Riley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7759, Bethesda, MD 20892, 301–435–
2889, rileyann@csr.nih.gov.
Name of Committee: Genes, Genomes, and
Genetics Integrated Review Group Molecular
Genetics B Study Section.
Date: January 31–February 1, 2013.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Richard A Currie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5128,
MSC 7840, Bethesda, MD 20892, (301) 435–
1219, currieri@csr.nih.gov.
E:\FR\FM\02JAN1.SGM
02JAN1
110
Federal Register / Vol. 78, No. 1 / Wednesday, January 2, 2013 / Notices
tkelley on DSK3SPTVN1PROD with
Name of Committee: Cell Biology
Integrated Review Group Cellular Signaling
and Regulatory Systems Study Section.
Date: January 31–February 1, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street
NW., Washington, DC 20036.
Contact Person: Elena Smirnova, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5187,
MSC 7840, Bethesda, MD 20892, 301–357–
9112, smirnove@csr.nih.gov.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group Clinical Neuroplasticity and
Neurotransmitters Study Section.
Date: January 31–February 1, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Melrose Hotel, 2430 Pennsylvania
Avenue NW., Washington, DC 20037.
Contact Person: Suzan Nadi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217B,
MSC 7846, Bethesda, MD 20892, 301–435–
1259, nadis@csr.nih.gov.
Name of Committee: Oncology 1-Basic
Translational Integrated Review Group
Cancer Etiology Study Section.
Date: January 31, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Westin Riverwalk, 420 W. Market
Street, San Antonio, TX 78205.
Contact Person: Elaine Sierra-Rivera, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6184,
MSC 7804, Bethesda, MD 20892, 301–435–
1779, riverase@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: Bioengineering Sciences and
Technology.
Date: January 31, 2013.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Kee Hyang Pyon, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5148,
MSC 7806, Bethesda, MD 20892,
pyonkh2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 26, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–31451 Filed 12–31–12; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
16:42 Dec 31, 2012
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Supplemental Record of Decision;
Final Supplementary Risk Assessment
for the Boston University National
Emerging Infectious Diseases
Laboratories
Responsible Official: Daniel G.
Wheeland, Director, Office of Research
Facilities Development and Operations,
National Institutes of Health.
SUMMARY: The Department of Health and
Human Services, the National Institutes
of Health (NIH), has decided, after
completion of a Final Supplementary
Risk Assessment and a thorough
consideration of public comments on
the Draft and Final Supplementary Risk
Assessment, to implement the Proposed
Action, which is identified as the
Preferred Alternative in the Final
Environmental Impact Statement (EIS).
This action reaffirms the NIH’s previous
decision to partially fund the
construction of a state-of-the-art
National Biocontainment Laboratory
(NBL), the National Emerging Infectious
Diseases Laboratories (NEIDL), at the
Boston University Medical Campus
(BUMC) in Boston, Massachusetts.
FOR FURTHER INFORMATION CONTACT: For
further information on the Record of
Decision: Valerie Nottingham, Chief,
Environmental Quality Branch, Office of
Research Facilities, National Institutes
of Health, 9000 Rockville Pike, Bld. 13/
2S11, Bethesda, MD 20892
nihnepa@mail.nih.gov.
For further information on the
Supplementary Risk Assessment: Kelly
Fennington, Senior Health Policy
Analyst, Office of Science Policy,
National Institutes of Health, 6705
Rockledge Drive, Suite 750, Bethesda,
MD 20892, 301–496–9838
NIH_BRP@od.nih.gov.
SUPPLEMENTARY INFORMATION: The
National Institutes of Health (NIH), an
operating division of the Department of
Health and Human Services (HHS), has
decided, after completion of a Final
Supplementary Risk Assessment for the
Boston University (BU) National
Emerging Infectious Diseases
Laboratories (NEIDL) and a thorough
consideration of the public comments
on the Draft and Final Supplementary
Risk Assessments, that the NEIDL, in its
current location in the BioSquare
Research Park, poses minimal risk to the
community surrounding the facility.
The Final Supplementary Risk
Assessment extensively evaluated
scenarios involving the potential human
health consequences of an exposure to
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
laboratory workers and members of the
general public as a result of
unintentional or malevolent events. The
Final Supplementary Risk Assessment
also analyzed the potential human
health impacts of siting the NEIDL at
two alternate locations from the current
site in Boston. The Final Supplementary
Risk Assessment concluded that the risk
to the public was generally low,
regardless of where the facility was
located. The analysis also showed there
was no disproportionate impact to the
residents living in the environmental
justice communities adjacent to the
NEIDL’s current location or to any
environmental justice communities at
either of the two alternative locations
analyzed. Based on the results of the
Final Supplementary Risk Assessment,
NIH is reaffirming its prior Record of
Decision of January 26, 2006, published
in the Federal Register on February 2,
2006.
On January 26, 2006, the NIH signed
the Record of Decision (ROD) to
partially fund the construction of a
state-of the-art National Biocontainment
Laboratory, which is now known as the
NEIDL, on the Boston University
Medical Campus in Boston,
Massachusetts. The NEIDL is a research
facility that was designed to include
high- and maximum-containment
laboratories for research on emerging
and re-emerging infectious diseases. The
ROD was posted in the Federal Register
on February 2, 2006, and described the
Proposed Action and alternatives
considered in the NIH’s Environmental
Impact Statement for the NEIDL. The
ROD also described many of the
physical characteristics of the NEIDL
and the safeguards that would be in
place for research conducted in the
building.
After the ROD was released, some
members of the public continued to
have concerns about the safety and
environmental impact of the facility.
Several citizens and public interest
groups filed lawsuits in Federal court to
stop the NIH’s partial funding of the
NEIDL’s construction. Opponents also
filed a lawsuit in Massachusetts state
court challenging the state’s approval of
the project. Both lawsuits alleged failure
to adequately assess the potential
impacts of the NEIDL on public health
in alternative locations. In the Federal
court proceedings, questions were
raised specifically about the potential
risks of the biosafety level 4 (BSL–4)
laboratory. To address the concerns
raised in these lawsuits, NIH established
an independent Blue Ribbon Panel to
advise the agency on comprehensively
responding to the concerns raised by
members of the community and by the
E:\FR\FM\02JAN1.SGM
02JAN1
]]>Agencies
[Federal Register Volume 78, Number 1 (Wednesday, January 2, 2013)]
[Notices]
[Pages 109-110]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-31451]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Bioengineering Sciences & Technologies
Integrated Review Group Nanotechnology Study Section.
Date: January 31-February 1, 2013.
Time: 7:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hotel Nikko San Francisco, 222 Mason Street, San
Francisco, CA 94102.
Contact Person: James J Li, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5148, MSC 7849, Bethesda, MD 20892, 301-806-
8065, lijames@csr.nih.gov.
Name of Committee: Risk, Prevention and Health Behavior
Integrated Review Group Psychosocial Development, Risk and
Prevention Study Section.
Date: January 31-February 1, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Renaissance Washington DC, Dupont Circle, 1143 New
Hampshire Avenue NW., Washington, DC 20037.
Contact Person: Anna L Riley, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3114, MSC 7759, Bethesda, MD 20892, 301-435-
2889, rileyann@csr.nih.gov.
Name of Committee: Genes, Genomes, and Genetics Integrated
Review Group Molecular Genetics B Study Section.
Date: January 31-February 1, 2013.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Richard A Currie, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5128, MSC 7840, Bethesda, MD
20892, (301) 435-1219, currieri@csr.nih.gov.
[[Page 110]]
Name of Committee: Cell Biology Integrated Review Group Cellular
Signaling and Regulatory Systems Study Section.
Date: January 31-February 1, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: St. Gregory Hotel, 2033 M Street NW., Washington, DC
20036.
Contact Person: Elena Smirnova, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5187, MSC 7840, Bethesda, MD
20892, 301-357-9112, smirnove@csr.nih.gov.
Name of Committee: Brain Disorders and Clinical Neuroscience
Integrated Review Group Clinical Neuroplasticity and
Neurotransmitters Study Section.
Date: January 31-February 1, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Melrose Hotel, 2430 Pennsylvania Avenue NW., Washington,
DC 20037.
Contact Person: Suzan Nadi, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5217B, MSC 7846, Bethesda, MD 20892, 301-435-
1259, nadis@csr.nih.gov.
Name of Committee: Oncology 1-Basic Translational Integrated
Review Group Cancer Etiology Study Section.
Date: January 31, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Westin Riverwalk, 420 W. Market Street, San Antonio, TX
78205.
Contact Person: Elaine Sierra-Rivera, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6184, MSC 7804, Bethesda, MD
20892, 301-435-1779, riverase@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel Member Conflict: Bioengineering Sciences and Technology.
Date: January 31, 2013.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Kee Hyang Pyon, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5148, MSC 7806, Bethesda, MD
20892, pyonkh2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: December 26, 2012.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-31451 Filed 12-31-12; 8:45 am]
BILLING CODE 4140-01-P
